|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Immune system
|
 |
|
Title:
|
 |
Crystal structure of the tv8 hybrid of human tlr4 and hagfish vlrb.61
|
|
Structure:
|
 |
Toll-like receptor 4, variable lymphocyte receptor b. Chain: a. Fragment: tlr4, unp residues 27-527(human), vlrb.61, unp residues 133-199(inshore hagfish). Synonym: htoll, cd284 antigen, tv8. Engineered: yes
|
|
Source:
|
 |
Homo sapiens, eptatretus burgeri. Human, inshore hagfish. Organism_taxid: 9606, 7764. Gene: tlr4, vlrb.61. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108.
|
|
Resolution:
|
 |
|
2.00Å
|
R-factor:
|
0.251
|
R-free:
|
0.298
|
|
|
Authors:
|
 |
H.M.Kim,B.S.Park,J.-O.Lee
|
Key ref:
|
 |
H.M.Kim
et al.
(2007).
Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.
Cell,
130,
906-917.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
22-Jul-07
|
Release date:
|
18-Sep-07
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.2.2.6
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
NAD+ + H2O = ADP-D-ribose + nicotinamide + H+
|
 |
 |
 |
 |
 |
NAD(+)
|
+
|
H2O
|
=
|
ADP-D-ribose
|
+
|
nicotinamide
|
+
|
H(+)
Bound ligand (Het Group name = )
matches with 43.75% similarity
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Cell
130:906-917
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.
|
|
H.M.Kim,
B.S.Park,
J.I.Kim,
S.E.Kim,
J.Lee,
S.C.Oh,
P.Enkhbayar,
N.Matsushima,
H.Lee,
O.J.Yoo,
J.O.Lee.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
TLR4 and MD-2 form a heterodimer that recognizes LPS (lipopolysaccharide) from
Gram-negative bacteria. Eritoran is an analog of LPS that antagonizes its
activity by binding to the TLR4-MD-2 complex. We determined the structure of the
full-length ectodomain of the mouse TLR4 and MD-2 complex. We also produced a
series of hybrids of human TLR4 and hagfish VLR and determined their structures
with and without bound MD-2 and Eritoran. TLR4 is an atypical member of the LRR
family and is composed of N-terminal, central, and C-terminal domains. The beta
sheet of the central domain shows unusually small radii and large twist angles.
MD-2 binds to the concave surface of the N-terminal and central domains. The
interaction with Eritoran is mediated by a hydrophobic internal pocket in MD-2.
Based on structural analysis and mutagenesis experiments on MD-2 and TLR4, we
propose a model of TLR4-MD-2 dimerization induced by LPS.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. Overall Structure of the Mouse TLR4-MD-2 Complex
(A–C) Three views of the mouse TLR4-MD-2 complex are
shown in the diagrams. The N-terminal, central, and C-terminal
domains of TLR4 are colored in blue, cyan, and green,
respectively. The beta strands of MD-2 are shown in pink and
red, and the LRR modules of TLR4 are numbered. (D) Closeup
view of mouse MD-2. Disulfide bridges are shown in yellow and
cysteines are labeled. Cys133 is not involved in the disulfide
bridge formation. The orientation of this view is the same as
for (C).
|
 |
Figure 4.
Figure 4. Assembly of the Full-Length Ectodomain of Human
TLR4 Structures of the three human TLR4-VLRB.61 hybrids.
TLR4 fragments are colored blue and VLRB.61 fragments gray. The
full-length ectodomain of human TLR4 was assembled after
superimposition of the overlapping regions of the TV8 and VT3
hybrids. The disulfide bridges are represented in orange.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Cell
(2007,
130,
906-917)
copyright 2007.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Barochia,
S.Solomon,
X.Cui,
C.Natanson,
and
P.Q.Eichacker
(2011).
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
|
| |
Expert Opin Drug Metab Toxicol,
7,
479-494.
|
 |
|
|
|
|
 |
A.C.Shaw,
A.Panda,
S.R.Joshi,
F.Qian,
H.G.Allore,
and
R.R.Montgomery
(2011).
Dysregulation of human Toll-like receptor function in aging.
|
| |
Ageing Res Rev,
10,
346-353.
|
 |
|
|
|
|
 |
E.Roh,
H.S.Lee,
J.A.Kwak,
J.T.Hong,
S.Y.Nam,
S.H.Jung,
J.Y.Lee,
N.D.Kim,
S.B.Han,
and
Y.Kim
(2011).
MD-2 as the target of nonlipid chalcone in the inhibition of endotoxin LPS-induced TLR4 activity.
|
| |
J Infect Dis,
203,
1012-1020.
|
 |
|
|
|
|
 |
H.Kumar,
T.Kawai,
and
S.Akira
(2011).
Pathogen recognition by the innate immune system.
|
| |
Int Rev Immunol,
30,
16-34.
|
 |
|
|
|
|
 |
H.Shinkai,
R.Suzuki,
M.Akiba,
N.Okumura,
and
H.Uenishi
(2011).
Porcine Toll-like receptors: recognition of Salmonella enterica serovar Choleraesuis and influence of polymorphisms.
|
| |
Mol Immunol,
48,
1114-1120.
|
 |
|
|
|
|
 |
I.Botos,
D.M.Segal,
and
D.R.Davies
(2011).
The structural biology of Toll-like receptors.
|
| |
Structure,
19,
447-459.
|
 |
|
|
|
|
 |
J.C.Bessot,
and
G.Pauli
(2011).
[House dust mites allergens.]
|
| |
Rev Mal Respir,
28,
475-495.
|
 |
|
|
|
|
 |
J.Campbell,
D.Lowe,
and
M.A.Sleeman
(2011).
Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.
|
| |
Br J Pharmacol,
162,
1470-1484.
|
 |
|
|
|
|
 |
J.J.Khoo,
S.Forster,
and
A.Mansell
(2011).
Toll-like receptors as interferon-regulated genes and their role in disease.
|
| |
J Interferon Cytokine Res,
31,
13-25.
|
 |
|
|
|
|
 |
M.Alcaide,
and
S.V.Edwards
(2011).
Molecular evolution of the toll-like receptor multigene family in birds.
|
| |
Mol Biol Evol,
28,
1703-1715.
|
 |
|
|
|
|
 |
S.I.Yoon,
M.Hong,
and
I.A.Wilson
(2011).
An unusual dimeric structure and assembly for TLR4 regulator RP105-MD-1.
|
| |
Nat Struct Mol Biol,
18,
1028-1035.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.Boehm
(2011).
Design principles of adaptive immune systems.
|
| |
Nat Rev Immunol,
11,
307-317.
|
 |
|
|
|
|
 |
T.J.Coffey,
and
D.Werling
(2011).
Therapeutic targeting of the innate immune system in domestic animals.
|
| |
Cell Tissue Res,
343,
251-261.
|
 |
|
|
|
|
 |
T.Wei,
J.Gong,
S.C.Rössle,
F.Jamitzky,
W.M.Heckl,
and
R.W.Stark
(2011).
A leucine-rich repeat assembly approach for homology modeling of the human TLR5-10 and mouse TLR11-13 ectodomains.
|
| |
J Mol Model,
17,
27-36.
|
 |
|
|
|
|
 |
A.I.Tukhvatulin,
D.Y.Logunov,
D.N.Shcherbinin,
M.M.Shmarov,
B.S.Naroditsky,
A.V.Gudkov,
and
A.L.Gintsburg
(2010).
Toll-like receptors and their adapter molecules.
|
| |
Biochemistry (Mosc),
75,
1098-1114.
|
 |
|
|
|
|
 |
A.M.Piccinini,
and
K.S.Midwood
(2010).
DAMPening inflammation by modulating TLR signalling.
|
| |
Mediators Inflamm,
2010,
0.
|
 |
|
|
|
|
 |
A.V.Chervonsky
(2010).
Influence of microbial environment on autoimmunity.
|
| |
Nat Immunol,
11,
28-35.
|
 |
|
|
|
|
 |
A.V.Kubarenko,
S.Ranjan,
E.Colak,
J.George,
M.Frank,
and
A.N.Weber
(2010).
Comprehensive modeling and functional analysis of Toll-like receptor ligand-recognition domains.
|
| |
Protein Sci,
19,
558-569.
|
 |
|
|
|
|
 |
A.X.Tran,
C.Dong,
and
C.Whitfield
(2010).
Structure and functional analysis of LptC, a conserved membrane protein involved in the lipopolysaccharide export pathway in Escherichia coli.
|
| |
J Biol Chem,
285,
33529-33539.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.van Mourik,
L.Steeghs,
J.van Laar,
H.D.Meiring,
H.J.Hamstra,
J.P.van Putten,
and
M.M.Wösten
(2010).
Altered linkage of hydroxyacyl chains in lipid A of Campylobacter jejuni reduces TLR4 activation and antimicrobial resistance.
|
| |
J Biol Chem,
285,
15828-15836.
|
 |
|
|
|
|
 |
B.Pamukcu,
G.Y.Lip,
A.Devitt,
H.Griffiths,
and
E.Shantsila
(2010).
The role of monocytes in atherosclerotic coronary artery disease.
|
| |
Ann Med,
42,
394-403.
|
 |
|
|
|
|
 |
C.E.Bryant,
D.R.Spring,
M.Gangloff,
and
N.J.Gay
(2010).
The molecular basis of the host response to lipopolysaccharide.
|
| |
Nat Rev Microbiol,
8,
8.
|
 |
|
|
|
|
 |
C.L.Baumann,
I.M.Aspalter,
O.Sharif,
A.Pichlmair,
S.Blüml,
F.Grebien,
M.Bruckner,
P.Pasierbek,
K.Aumayr,
M.Planyavsky,
K.L.Bennett,
J.Colinge,
S.Knapp,
and
G.Superti-Furga
(2010).
CD14 is a coreceptor of Toll-like receptors 7 and 9.
|
| |
J Exp Med,
207,
2689-2701.
|
 |
|
|
|
|
 |
C.L.Karp
(2010).
Guilt by intimate association: what makes an allergen an allergen?
|
| |
J Allergy Clin Immunol,
125,
955.
|
 |
|
|
|
|
 |
C.R.Dunston,
and
H.R.Griffiths
(2010).
The effect of ageing on macrophage Toll-like receptor-mediated responses in the fight against pathogens.
|
| |
Clin Exp Immunol,
161,
407-416.
|
 |
|
|
|
|
 |
E.Y.Kim,
H.Y.Shin,
J.Y.Kim,
D.G.Kim,
Y.M.Choi,
H.K.Kwon,
D.K.Rhee,
Y.S.Kim,
and
S.Choi
(2010).
ATF3 plays a key role in Kdo2-lipid A-induced TLR4-dependent gene expression via NF-κB activation.
|
| |
PLoS One,
5,
e14181.
|
 |
|
|
|
|
 |
H.Fischer,
N.Lutay,
B.Ragnarsdóttir,
M.Yadav,
K.Jönsson,
A.Urbano,
A.Al Hadad,
S.Rämisch,
P.Storm,
U.Dobrindt,
E.Salvador,
D.Karpman,
U.Jodal,
and
C.Svanborg
(2010).
Pathogen specific, IRF3-dependent signaling and innate resistance to human kidney infection.
|
| |
PLoS Pathog,
6,
0.
|
 |
|
|
|
|
 |
H.Tsukamoto,
K.Fukudome,
S.Takao,
N.Tsuneyoshi,
and
M.Kimoto
(2010).
Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells.
|
| |
Int Immunol,
22,
271-280.
|
 |
|
|
|
|
 |
J.B.McPhee,
P.Mena,
and
J.B.Bliska
(2010).
Delineation of regions of the Yersinia YopM protein required for interaction with the RSK1 and PRK2 host kinases and their requirement for interleukin-10 production and virulence.
|
| |
Infect Immun,
78,
3529-3539.
|
 |
|
|
|
|
 |
J.B.Soares,
P.Pimentel-Nunes,
R.Roncon-Albuquerque,
and
A.Leite-Moreira
(2010).
The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.
|
| |
Hepatol Int,
4,
659-672.
|
 |
|
|
|
|
 |
J.C.Blanco,
M.S.Boukhvalova,
K.A.Shirey,
G.A.Prince,
and
S.N.Vogel
(2010).
New insights for development of a safe and protective RSV vaccine.
|
| |
Hum Vaccin,
6,
482-492.
|
 |
|
|
|
|
 |
J.Gong,
T.Wei,
N.Zhang,
F.Jamitzky,
W.M.Heckl,
S.C.Rössle,
and
R.W.Stark
(2010).
TollML: a database of toll-like receptor structural motifs.
|
| |
J Mol Model,
16,
1283-1289.
|
 |
|
|
|
|
 |
J.L.Krauss,
J.Potempa,
J.D.Lambris,
and
G.Hajishengallis
(2010).
Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host.
|
| |
Periodontol 2000,
52,
141-162.
|
 |
|
|
|
|
 |
J.Liu,
C.Xu,
L.C.Hsu,
Y.Luo,
R.Xiang,
and
T.H.Chuang
(2010).
A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition.
|
| |
Mol Immunol,
47,
1083-1090.
|
 |
|
|
|
|
 |
J.Petrasek,
P.Mandrekar,
and
G.Szabo
(2010).
Toll-like receptors in the pathogenesis of alcoholic liver disease.
|
| |
Gastroenterol Res Pract,
2010,
0.
|
 |
|
|
|
|
 |
J.R.Riddell,
X.Y.Wang,
H.Minderman,
and
S.O.Gollnick
(2010).
Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4.
|
| |
J Immunol,
184,
1022-1030.
|
 |
|
|
|
|
 |
J.Stagsted,
A.L.Jørgensen,
and
H.R.Juul-Madsen
(2010).
Mass spectrometric-based protein chips for detection of food-derived bioactive components.
|
| |
Ann N Y Acad Sci,
1190,
133-140.
|
 |
|
|
|
|
 |
M.Black,
A.Trent,
M.Tirrell,
and
C.Olive
(2010).
Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists.
|
| |
Expert Rev Vaccines,
9,
157-173.
|
 |
|
|
|
|
 |
M.Yamamoto,
and
K.Takeda
(2010).
Current views of toll-like receptor signaling pathways.
|
| |
Gastroenterol Res Pract,
2010,
240365.
|
 |
|
|
|
|
 |
N.Marr,
A.M.Hajjar,
N.R.Shah,
A.Novikov,
C.S.Yam,
M.Caroff,
and
R.C.Fernandez
(2010).
Substitution of the Bordetella pertussis lipid A phosphate groups with glucosamine is required for robust NF-kappaB activation and release of proinflammatory cytokines in cells expressing human but not murine Toll-like receptor 4-MD-2-CD14.
|
| |
Infect Immun,
78,
2060-2069.
|
 |
|
|
|
|
 |
N.Matsushima,
H.Miyashita,
T.Mikami,
and
Y.Kuroki
(2010).
A nested leucine rich repeat (LRR) domain: the precursor of LRRs is a ten or eleven residue motif.
|
| |
BMC Microbiol,
10,
235.
|
 |
|
|
|
|
 |
P.C.Ronald,
and
B.Beutler
(2010).
Plant and animal sensors of conserved microbial signatures.
|
| |
Science,
330,
1061-1064.
|
 |
|
|
|
|
 |
P.Prohinar,
P.Rallabhandi,
J.P.Weiss,
and
T.L.Gioannini
(2010).
Expression of functional D299G.T399I polymorphic variant of TLR4 depends more on coexpression of MD-2 than does wild-type TLR4.
|
| |
J Immunol,
184,
4362-4367.
|
 |
|
|
|
|
 |
R.A.Mariuzza,
C.A.Velikovsky,
L.Deng,
G.Xu,
and
Z.Pancer
(2010).
Structural insights into the evolution of the adaptive immune system: the variable lymphocyte receptors of jawless vertebrates.
|
| |
Biol Chem,
391,
753-760.
|
 |
|
|
|
|
 |
R.Ostuni,
I.Zanoni,
and
F.Granucci
(2010).
Deciphering the complexity of Toll-like receptor signaling.
|
| |
Cell Mol Life Sci,
67,
4109-4134.
|
 |
|
|
|
|
 |
S.I.Yoon,
M.Hong,
G.W.Han,
and
I.A.Wilson
(2010).
Crystal structure of soluble MD-1 and its interaction with lipid IVa.
|
| |
Proc Natl Acad Sci U S A,
107,
10990-10995.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Kusumoto,
K.Fukase,
and
T.Shiba
(2010).
Key structures of bacterial peptidoglycan and lipopolysaccharide triggering the innate immune system of higher animals: chemical synthesis and functional studies.
|
| |
Proc Jpn Acad Ser B Phys Biol Sci,
86,
322-337.
|
 |
|
|
|
|
 |
S.M.Leal,
S.Cowden,
Y.C.Hsia,
M.A.Ghannoum,
M.Momany,
and
E.Pearlman
(2010).
Distinct roles for Dectin-1 and TLR4 in the pathogenesis of Aspergillus fumigatus keratitis.
|
| |
PLoS Pathog,
6,
e1000976.
|
 |
|
|
|
|
 |
T.Kawai,
and
S.Akira
(2010).
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.
|
| |
Nat Immunol,
11,
373-384.
|
 |
|
|
|
|
 |
X.Wittebole,
D.Castanares-Zapatero,
and
P.F.Laterre
(2010).
Toll-like receptor 4 modulation as a strategy to treat sepsis.
|
| |
Mediators Inflamm,
2010,
568396.
|
 |
|
|
|
|
 |
Z.L.Chang
(2010).
Important aspects of Toll-like receptors, ligands and their signaling pathways.
|
| |
Inflamm Res,
59,
791-808.
|
 |
|
|
|
|
 |
A.Bhunia,
H.Mohanram,
and
S.Bhattacharjya
(2009).
Lipopolysaccharide bound structures of the active fragments of fowlicidin-1, a cathelicidin family of antimicrobial and antiendotoxic peptide from chicken, determined by transferred nuclear overhauser effect spectroscopy.
|
| |
Biopolymers,
92,
9.
|
 |
|
|
|
|
 |
A.Chaturvedi,
and
S.K.Pierce
(2009).
How location governs toll-like receptor signaling.
|
| |
Traffic,
10,
621-628.
|
 |
|
|
|
|
 |
A.Mencin,
J.Kluwe,
and
R.F.Schwabe
(2009).
Toll-like receptors as targets in chronic liver diseases.
|
| |
Gut,
58,
704-720.
|
 |
|
|
|
|
 |
A.Schaeffler,
P.Gross,
R.Buettner,
C.Bollheimer,
C.Buechler,
M.Neumeier,
A.Kopp,
J.Schoelmerich,
and
W.Falk
(2009).
Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity.
|
| |
Immunology,
126,
233-245.
|
 |
|
|
|
|
 |
A.Trompette,
S.Divanovic,
A.Visintin,
C.Blanchard,
R.S.Hegde,
R.Madan,
P.S.Thorne,
M.Wills-Karp,
T.L.Gioannini,
J.P.Weiss,
and
C.L.Karp
(2009).
Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein.
|
| |
Nature,
457,
585-588.
|
 |
|
|
|
|
 |
B.Beutler
(2009).
Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases.
|
| |
Immunol Rev,
227,
248-263.
|
 |
|
|
|
|
 |
B.S.Park,
D.H.Song,
H.M.Kim,
B.S.Choi,
H.Lee,
and
J.O.Lee
(2009).
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex.
|
| |
Nature,
458,
1191-1195.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.A.Velikovsky,
L.Deng,
S.Tasumi,
L.M.Iyer,
M.C.Kerzic,
L.Aravind,
Z.Pancer,
and
R.A.Mariuzza
(2009).
Structure of a lamprey variable lymphocyte receptor in complex with a protein antigen.
|
| |
Nat Struct Mol Biol,
16,
725-730.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Kojima-Shibata,
H.Shinkai,
T.Morozumi,
K.Jozaki,
D.Toki,
T.Matsumoto,
H.Kadowaki,
E.Suzuki,
and
H.Uenishi
(2009).
Differences in distribution of single nucleotide polymorphisms among intracellular pattern recognition receptors in pigs.
|
| |
Immunogenetics,
61,
153-160.
|
 |
|
|
|
|
 |
C.Morales,
S.Wu,
Y.Yang,
B.Hao,
and
Z.Li
(2009).
Drosophila glycoprotein 93 Is an ortholog of mammalian heat shock protein gp96 (grp94, HSP90b1, HSPC4) and retains disulfide bond-independent chaperone function for TLRs and integrins.
|
| |
J Immunol,
183,
5121-5128.
|
 |
|
|
|
|
 |
C.Nishitani,
M.Takahashi,
H.Mitsuzawa,
T.Shimizu,
S.Ariki,
N.Matsushima,
and
Y.Kuroki
(2009).
Mutational analysis of Cys(88) of Toll-like receptor 4 highlights the critical role of MD-2 in cell surface receptor expression.
|
| |
Int Immunol,
21,
925-934.
|
 |
|
|
|
|
 |
C.R.Raetz,
Z.Guan,
B.O.Ingram,
D.A.Six,
F.Song,
X.Wang,
and
J.Zhao
(2009).
Discovery of new biosynthetic pathways: the lipid A story.
|
| |
J Lipid Res,
50,
S103-S108.
|
 |
|
|
|
|
 |
D.S.Stephens
(2009).
Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis.
|
| |
Vaccine,
27,
B71-B77.
|
 |
|
|
|
|
 |
D.T.O'Hagan,
and
E.De Gregorio
(2009).
The path to a successful vaccine adjuvant--'the long and winding road'.
|
| |
Drug Discov Today,
14,
541-551.
|
 |
|
|
|
|
 |
D.Werling,
O.C.Jann,
V.Offord,
E.J.Glass,
and
T.J.Coffey
(2009).
Variation matters: TLR structure and species-specific pathogen recognition.
|
| |
Trends Immunol,
30,
124-130.
|
 |
|
|
|
|
 |
G.Hajishengallis
(2009).
Toll gates to periodontal host modulation and vaccine therapy.
|
| |
Periodontol 2000,
51,
181-207.
|
 |
|
|
|
|
 |
G.M.Barton,
and
J.C.Kagan
(2009).
A cell biological view of Toll-like receptor function: regulation through compartmentalization.
|
| |
Nat Rev Immunol,
9,
535-542.
|
 |
|
|
|
|
 |
H.Kumar,
T.Kawai,
and
S.Akira
(2009).
Pathogen recognition in the innate immune response.
|
| |
Biochem J,
420,
1.
|
 |
|
|
|
|
 |
H.Shin,
Y.Zhang,
M.Jagannathan,
H.Hasturk,
A.Kantarci,
H.Liu,
T.E.Van Dyke,
L.M.Ganley-Leal,
and
B.S.Nikolajczyk
(2009).
B cells from periodontal disease patients express surface Toll-like receptor 4.
|
| |
J Leukoc Biol,
85,
648-655.
|
 |
|
|
|
|
 |
I.Botos,
L.Liu,
Y.Wang,
D.M.Segal,
and
D.R.Davies
(2009).
The toll-like receptor 3:dsRNA signaling complex.
|
| |
Biochim Biophys Acta,
1789,
667-674.
|
 |
|
|
|
|
 |
J.A.Wright,
S.S.Tötemeyer,
I.Hautefort,
C.Appia-Ayme,
M.Alston,
V.Danino,
G.K.Paterson,
P.Mastroeni,
N.Ménager,
M.Rolfe,
A.Thompson,
S.Ugrinovic,
L.Sait,
T.Humphrey,
H.Northen,
S.E.Peters,
D.J.Maskell,
J.C.Hinton,
and
C.E.Bryant
(2009).
Multiple redundant stress resistance mechanisms are induced in Salmonella enterica serovar Typhimurium in response to alteration of the intracellular environment via TLR4 signalling.
|
| |
Microbiology,
155,
2919-2929.
|
 |
|
|
|
|
 |
J.Vasl,
A.Oblak,
T.L.Gioannini,
J.P.Weiss,
and
R.Jerala
(2009).
Novel roles of lysines 122, 125, and 58 in functional differences between human and murine MD-2.
|
| |
J Immunol,
183,
5138-5145.
|
 |
|
|
|
|
 |
J.Y.Kang,
X.Nan,
M.S.Jin,
S.J.Youn,
Y.H.Ryu,
S.Mah,
S.H.Han,
H.Lee,
S.G.Paik,
and
J.O.Lee
(2009).
Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer.
|
| |
Immunity,
31,
873-884.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.D.Smith
(2009).
Toll-like receptors in kidney disease.
|
| |
Curr Opin Nephrol Hypertens,
18,
189-196.
|
 |
|
|
|
|
 |
K.Jung,
J.E.Lee,
H.Z.Kim,
H.M.Kim,
B.S.Park,
S.I.Hwang,
J.O.Lee,
S.C.Kim,
and
G.Y.Koh
(2009).
Toll-like receptor 4 decoy, TOY, attenuates gram-negative bacterial sepsis.
|
| |
PLoS One,
4,
e7403.
|
 |
|
|
|
|
 |
K.L.Hindle,
J.Bella,
and
S.C.Lovell
(2009).
Quantitative analysis and prediction of curvature in leucine-rich repeat proteins.
|
| |
Proteins,
77,
342-358.
|
 |
|
|
|
|
 |
K.Midwood,
S.Sacre,
A.M.Piccinini,
J.Inglis,
A.Trebaul,
E.Chan,
S.Drexler,
N.Sofat,
M.Kashiwagi,
G.Orend,
F.Brennan,
and
B.Foxwell
(2009).
Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.
|
| |
Nat Med,
15,
774-780.
|
 |
|
|
|
|
 |
L.A.O'Neill,
C.E.Bryant,
and
S.L.Doyle
(2009).
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.
|
| |
Pharmacol Rev,
61,
177-197.
|
 |
|
|
|
|
 |
M.J.Jimenez-Dalmaroni,
N.Xiao,
A.L.Corper,
P.Verdino,
G.D.Ainge,
D.S.Larsen,
G.F.Painter,
P.M.Rudd,
R.A.Dwek,
K.Hoebe,
B.Beutler,
and
I.A.Wilson
(2009).
Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2.
|
| |
PLoS One,
4,
e7411.
|
 |
|
|
|
|
 |
M.J.Karbarz,
D.A.Six,
and
C.R.Raetz
(2009).
Purification and characterization of the lipid A 1-phosphatase LpxE of Rhizobium leguminosarum.
|
| |
J Biol Chem,
284,
414-425.
|
 |
|
|
|
|
 |
M.Mancek-Keber,
H.Gradisar,
M.I.Pestaña,
G.Martinez de Tejada,
and
R.Jerala
(2009).
Free Thiol Group of MD-2 as the Target for Inhibition of the Lipopolysaccharide-induced Cell Activation.
|
| |
J Biol Chem,
284,
19493-19500.
|
 |
|
|
|
|
 |
M.Piazza,
L.Yu,
A.Teghanemt,
T.Gioannini,
J.Weiss,
and
F.Peri
(2009).
Evidence of a specific interaction between new synthetic antisepsis agents and CD14.
|
| |
Biochemistry,
48,
12337-12344.
|
 |
|
|
|
|
 |
N.Resman,
J.Vasl,
A.Oblak,
P.Pristovsek,
T.L.Gioannini,
J.P.Weiss,
and
R.Jerala
(2009).
Essential Roles of Hydrophobic Residues in Both MD-2 and Toll-like Receptor 4 in Activation by Endotoxin.
|
| |
J Biol Chem,
284,
15052-15060.
|
 |
|
|
|
|
 |
P.F.Slivka,
M.Shridhar,
G.I.Lee,
D.W.Sammond,
M.R.Hutchinson,
A.J.Martinko,
M.M.Buchanan,
P.W.Sholar,
J.J.Kearney,
J.A.Harrison,
L.R.Watkins,
and
H.Yin
(2009).
A peptide antagonist of the TLR4-MD2 interaction.
|
| |
Chembiochem,
10,
645-649.
|
 |
|
|
|
|
 |
P.Georgel,
C.Macquin,
and
S.Bahram
(2009).
The heterogeneous allelic repertoire of human toll-like receptor (TLR) genes.
|
| |
PLoS One,
4,
e7803.
|
 |
|
|
|
|
 |
P.Gross,
K.Brandl,
C.Dierkes,
J.Schölmerich,
B.Salzberger,
T.Glück,
and
W.Falk
(2009).
Lipopolysaccharide-trap-Fc, a multifunctional agent to battle gram-negative bacteria.
|
| |
Infect Immun,
77,
2925-2931.
|
 |
|
|
|
|
 |
P.Tissières,
and
J.Pugin
(2009).
The role of MD-2 in the opsonophagocytosis of Gram-negative bacteria.
|
| |
Curr Opin Infect Dis,
22,
286-291.
|
 |
|
|
|
|
 |
R.I.Tapping
(2009).
Innate immune sensing and activation of cell surface Toll-like receptors.
|
| |
Semin Immunol,
21,
175-184.
|
 |
|
|
|
|
 |
R.Munford,
M.Lu,
and
A.Varley
(2009).
Chapter 2: Kill the bacteria...and also their messengers?
|
| |
Adv Immunol,
103,
29-48.
|
 |
|
|
|
|
 |
R.N.Coler,
D.Carter,
M.Friede,
and
S.G.Reed
(2009).
Adjuvants for malaria vaccines.
|
| |
Parasite Immunol,
31,
520-528.
|
 |
|
|
|
|
 |
S.Cai,
R.L.Zemans,
S.K.Young,
G.S.Worthen,
and
S.Jeyaseelan
(2009).
Myeloid differentiation protein-2-dependent and -independent neutrophil accumulation during Escherichia coli pneumonia.
|
| |
Am J Respir Cell Mol Biol,
40,
701-709.
|
 |
|
|
|
|
 |
S.Carpenter,
and
L.A.O'Neill
(2009).
Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins.
|
| |
Biochem J,
422,
1.
|
 |
|
|
|
|
 |
S.Ichikawa,
T.Takai,
T.Yashiki,
S.Takahashi,
K.Okumura,
H.Ogawa,
D.Kohda,
and
H.Hatanaka
(2009).
Lipopolysaccharide binding of the mite allergen Der f 2.
|
| |
Genes Cells,
14,
1055-1065.
|
 |
|
|
|
|
 |
S.Liang,
K.B.Hosur,
S.Lu,
H.F.Nawar,
B.R.Weber,
R.I.Tapping,
T.D.Connell,
and
G.Hajishengallis
(2009).
Mapping of a microbial protein domain involved in binding and activation of the TLR2/TLR1 heterodimer.
|
| |
J Immunol,
182,
2978-2985.
|
 |
|
|
|
|
 |
S.M.Opal,
and
E.Patrozou
(2009).
Translational research in the development of novel sepsis therapeutics: logical deductive reasoning or mission impossible?
|
| |
Crit Care Med,
37,
S10-S15.
|
 |
|
|
|
|
 |
T.H.Mogensen
(2009).
Pathogen recognition and inflammatory signaling in innate immune defenses.
|
| |
Clin Microbiol Rev,
22,
240.
|
 |
|
|
|
|
 |
T.Kawai,
and
S.Akira
(2009).
The roles of TLRs, RLRs and NLRs in pathogen recognition.
|
| |
Int Immunol,
21,
317-337.
|
 |
|
|
|
|
 |
T.Lögters,
S.Margraf,
J.Altrichter,
J.Cinatl,
S.Mitzner,
J.Windolf,
and
M.Scholz
(2009).
The clinical value of neutrophil extracellular traps.
|
| |
Med Microbiol Immunol,
198,
211-219.
|
 |
|
|
|
|
 |
T.P.Monie,
C.E.Bryant,
and
N.J.Gay
(2009).
Activating immunity: lessons from the TLRs and NLRs.
|
| |
Trends Biochem Sci,
34,
553-561.
|
 |
|
|
|
|
 |
T.Roger,
C.Froidevaux,
D.Le Roy,
M.K.Reymond,
A.L.Chanson,
D.Mauri,
K.Burns,
B.M.Riederer,
S.Akira,
and
T.Calandra
(2009).
Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4.
|
| |
Proc Natl Acad Sci U S A,
106,
2348-2352.
|
 |
|
|
|
|
 |
T.V.Arumugam,
E.Okun,
S.C.Tang,
J.Thundyil,
S.M.Taylor,
and
T.M.Woodruff
(2009).
Toll-like receptors in ischemia-reperfusion injury.
|
| |
Shock,
32,
4.
|
 |
|
|
|
|
 |
T.Wei,
J.Gong,
F.Jamitzky,
W.M.Heckl,
R.W.Stark,
and
S.C.Rössle
(2009).
Homology modeling of human Toll-like receptors TLR7, 8, and 9 ligand-binding domains.
|
| |
Protein Sci,
18,
1684-1691.
|
 |
|
|
|
|
 |
T.Xiao
(2009).
Innate immune recognition of nucleic acids.
|
| |
Immunol Res,
43,
98.
|
 |
|
|
|
|
 |
W.J.McCormack,
A.E.Parker,
and
L.A.O'Neill
(2009).
Toll-like receptors and NOD-like receptors in rheumatic diseases.
|
| |
Arthritis Res Ther,
11,
243.
|
 |
|
|
|
|
 |
X.Wang,
A.A.Ribeiro,
Z.Guan,
and
C.R.Raetz
(2009).
Identification of undecaprenyl phosphate-beta-D-galactosamine in Francisella novicida and its function in lipid A modification.
|
| |
Biochemistry,
48,
1162-1172.
|
 |
|
|
|
|
 |
A.K.Randhawa,
and
T.R.Hawn
(2008).
Toll-like receptors: their roles in bacterial recognition and respiratory infections.
|
| |
Expert Rev Anti Infect Ther,
6,
479-495.
|
 |
|
|
|
|
 |
A.R.Ashtekar,
P.Zhang,
J.Katz,
C.C.Deivanayagam,
P.Rallabhandi,
S.N.Vogel,
and
S.M.Michalek
(2008).
TLR4-mediated activation of dendritic cells by the heat shock protein DnaK from Francisella tularensis.
|
| |
J Leukoc Biol,
84,
1434-1446.
|
 |
|
|
|
|
 |
A.Teghanemt,
F.Re,
P.Prohinar,
R.Widstrom,
T.L.Gioannini,
and
J.P.Weiss
(2008).
Novel roles in human MD-2 of phenylalanines 121 and 126 and tyrosine 131 in activation of Toll-like receptor 4 by endotoxin.
|
| |
J Biol Chem,
283,
1257-1266.
|
 |
|
|
|
|
 |
B.Ferwerda,
M.B.McCall,
K.Verheijen,
B.J.Kullberg,
A.J.van der Ven,
J.W.Van der Meer,
and
M.G.Netea
(2008).
Functional consequences of toll-like receptor 4 polymorphisms.
|
| |
Mol Med,
14,
346-352.
|
 |
|
|
|
|
 |
B.W.Han,
B.R.Herrin,
M.D.Cooper,
and
I.A.Wilson
(2008).
Antigen recognition by variable lymphocyte receptors.
|
| |
Science,
321,
1834-1837.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Erridge,
S.Kennedy,
C.M.Spickett,
and
D.J.Webb
(2008).
Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition.
|
| |
J Biol Chem,
283,
24748-24759.
|
 |
|
|
|
|
 |
C.G.Leon,
R.Tory,
J.Jia,
O.Sivak,
and
K.M.Wasan
(2008).
Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases.
|
| |
Pharm Res,
25,
1751-1761.
|
 |
|
|
|
|
 |
C.M.Bartling,
and
C.R.Raetz
(2008).
Steady-state kinetics and mechanism of LpxD, the N-acyltransferase of lipid A biosynthesis.
|
| |
Biochemistry,
47,
5290-5302.
|
 |
|
|
|
|
 |
C.R.Casella,
and
T.C.Mitchell
(2008).
Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.
|
| |
Cell Mol Life Sci,
65,
3231-3240.
|
 |
|
|
|
|
 |
C.del Fresno,
V.Gómez-Piña,
V.Lores,
A.Soares-Schanoski,
I.Fernández-Ruiz,
B.Rojo,
R.Alvarez-Sala,
E.Caballero-Garrido,
F.García,
T.Veliz,
F.Arnalich,
P.Fuentes-Prior,
F.García-Río,
and
E.López-Collazo
(2008).
Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism.
|
| |
PLoS ONE,
3,
e2667.
|
 |
|
|
|
|
 |
D.A.Six,
S.M.Carty,
Z.Guan,
and
C.R.Raetz
(2008).
Purification and mutagenesis of LpxL, the lauroyltransferase of Escherichia coli lipid A biosynthesis.
|
| |
Biochemistry,
47,
8623-8637.
|
 |
|
|
|
|
 |
D.Rittirsch,
M.A.Flierl,
and
P.A.Ward
(2008).
Harmful molecular mechanisms in sepsis.
|
| |
Nat Rev Immunol,
8,
776-787.
|
 |
|
|
|
|
 |
H.Chi,
and
R.A.Flavell
(2008).
Innate recognition of non-self nucleic acids.
|
| |
Genome Biol,
9,
211.
|
 |
|
|
|
|
 |
H.Oshiumi,
A.Matsuo,
M.Matsumoto,
and
T.Seya
(2008).
Pan-vertebrate toll-like receptors during evolution.
|
| |
Curr Genomics,
9,
488-493.
|
 |
|
|
|
|
 |
H.Park,
J.Huxley-Jones,
R.P.Boot-Handford,
P.N.Bishop,
T.K.Attwood,
and
J.Bella
(2008).
LRRCE: a leucine-rich repeat cysteine capping motif unique to the chordate lineage.
|
| |
BMC Genomics,
9,
599.
|
 |
|
|
|
|
 |
J.N.Leonard,
R.Ghirlando,
J.Askins,
J.K.Bell,
D.H.Margulies,
D.R.Davies,
and
D.M.Segal
(2008).
The TLR3 signaling complex forms by cooperative receptor dimerization.
|
| |
Proc Natl Acad Sci U S A,
105,
258-263.
|
 |
|
|
|
|
 |
K.J.Ishii,
S.Koyama,
A.Nakagawa,
C.Coban,
and
S.Akira
(2008).
Host innate immune receptors and beyond: making sense of microbial infections.
|
| |
Cell Host Microbe,
3,
352-363.
|
 |
|
|
|
|
 |
M.Gangloff,
A.Murali,
J.Xiong,
C.J.Arnot,
A.N.Weber,
A.M.Sandercock,
C.V.Robinson,
R.Sarisky,
A.Holzenburg,
C.Kao,
and
N.J.Gay
(2008).
Structural insight into the mechanism of activation of the Toll receptor by the dimeric ligand Spätzle.
|
| |
J Biol Chem,
283,
14629-14635.
|
 |
|
|
|
|
 |
M.S.Butler
(2008).
Natural products to drugs: natural product-derived compounds in clinical trials.
|
| |
Nat Prod Rep,
25,
475-516.
|
 |
|
|
|
|
 |
M.S.Jin,
and
J.O.Lee
(2008).
Structures of TLR-ligand complexes.
|
| |
Curr Opin Immunol,
20,
414-419.
|
 |
|
|
|
|
 |
M.S.Jin,
and
J.O.Lee
(2008).
Structures of the toll-like receptor family and its ligand complexes.
|
| |
Immunity,
29,
182-191.
|
 |
|
|
|
|
 |
M.W.Hornef,
B.Henriques-Normark,
and
S.Normark
(2008).
The function and biological role of toll-like receptors in infectious diseases: an update.
|
| |
Curr Opin Infect Dis,
21,
304-312.
|
 |
|
|
|
|
 |
M.Yamazoe,
C.Nishitani,
M.Takahashi,
T.Katoh,
S.Ariki,
T.Shimizu,
H.Mitsuzawa,
K.Sawada,
D.R.Voelker,
H.Takahashi,
and
Y.Kuroki
(2008).
Pulmonary Surfactant Protein D Inhibits Lipopolysaccharide (LPS)-induced Inflammatory Cell Responses by Altering LPS Binding to Its Receptors.
|
| |
J Biol Chem,
283,
35878-35888.
|
 |
|
|
|
|
 |
P.Rallabhandi,
A.Awomoyi,
K.E.Thomas,
A.Phalipon,
Y.Fujimoto,
K.Fukase,
S.Kusumoto,
N.Qureshi,
M.B.Sztein,
and
S.N.Vogel
(2008).
Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling.
|
| |
J Immunol,
180,
1139-1147.
|
 |
|
|
|
|
 |
P.Tissières,
I.Dunn-Siegrist,
M.Schäppi,
G.Elson,
R.Comte,
V.Nobre,
and
J.Pugin
(2008).
Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria.
|
| |
Blood,
111,
2122-2131.
|
 |
|
|
|
|
 |
Q.R.Fan,
and
W.A.Hendrickson
(2008).
Comparative structural analysis of the binding domain of follicle stimulating hormone receptor.
|
| |
Proteins,
72,
393-401.
|
 |
|
|
|
|
 |
R.S.Munford
(2008).
Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?
|
| |
Infect Immun,
76,
454-465.
|
 |
|
|
|
|
 |
S.Akashi-Takamura,
and
K.Miyake
(2008).
TLR accessory molecules.
|
| |
Curr Opin Immunol,
20,
420-425.
|
 |
|
|
|
|
 |
S.M.Zimmer,
J.Liu,
J.L.Clayton,
D.S.Stephens,
and
J.P.Snyder
(2008).
Paclitaxel Binding to Human and Murine MD-2.
|
| |
J Biol Chem,
283,
27916-27926.
|
 |
|
|
|
|
 |
T.Gautier,
A.Klein,
V.Deckert,
C.Desrumaux,
N.Ogier,
A.L.Sberna,
C.Paul,
N.Le Guern,
A.Athias,
T.Montange,
S.Monier,
F.Piard,
X.C.Jiang,
D.Masson,
and
L.Lagrost
(2008).
Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice.
|
| |
J Biol Chem,
283,
18702-18710.
|
 |
|
|
|
|
 |
T.Kiyokawa,
S.Akashi-Takamura,
T.Shibata,
F.Matsumoto,
C.Nishitani,
Y.Kuroki,
Y.Seto,
and
K.Miyake
(2008).
A single base mutation in the PRAT4A gene reveals differential interaction of PRAT4A with Toll-like receptors.
|
| |
Int Immunol,
20,
1407-1415.
|
 |
|
|
|
|
 |
T.Sigsgaard,
H.J.Hoffmann,
and
P.S.Thorne
(2008).
The role of innate immunity in occupational allergy: recent findings.
|
| |
Curr Opin Allergy Clin Immunol,
8,
120-125.
|
 |
|
|
|
|
 |
V.Jain,
A.Halle,
K.A.Halmen,
E.Lien,
M.Charrel-Dennis,
S.Ram,
D.T.Golenbock,
and
A.Visintin
(2008).
Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling.
|
| |
Blood,
111,
4637-4645.
|
 |
|
|
|
|
 |
Y.Kumagai,
O.Takeuchi,
and
S.Akira
(2008).
Pathogen recognition by innate receptors.
|
| |
J Infect Chemother,
14,
86-92.
|
 |
|
|
|
|
 |
Y.Li,
A.R.Chase,
P.F.Slivka,
C.T.Baggett,
T.X.Zhao,
and
H.Yin
(2008).
Design, synthesis, and evaluation of biotinylated opioid derivatives as novel probes to study opioid pharmacology.
|
| |
Bioconjug Chem,
19,
2585-2589.
|
 |
|
|
|
|
 |
I.Brodsky,
and
R.Medzhitov
(2007).
Two modes of ligand recognition by TLRs.
|
| |
Cell,
130,
979-981.
|
 |
|
|
|
|
 |
M.S.Jin,
S.E.Kim,
J.Y.Heo,
M.E.Lee,
H.M.Kim,
S.G.Paik,
H.Lee,
and
J.O.Lee
(2007).
Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide.
|
| |
Cell,
130,
1071-1082.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |